The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting

Güler, Niyazi; Batyraliev, Talantbek; Dülger, Haluk; Ozkara, Cenap; Tuncer, Mustafa; Aslan, Sipan; Okut, Hayrettin; Ağırbaşlı, Mehmet

doi:10.1016/j.ijcard.2005.06.027

Cited by 29 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Already after 3 weeks of testosterone administration, a decline was noted in IL6 (63) and in another study after 16 weeks (64). A decrease in C-reactive protein (CRP) was observed after 3 weeks (63) and in other studies after 3 months (32, 43). In a study in patients with Crohn's disease, CRP levels continued to decline over 24 months (65).…”

Section: Time-course Of Effects On Inflammatory Factors/endothelial Mmentioning

confidence: 83%

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Saad

Aversa

Isidori

et al. 2011

European Journal of Endocrinology

198

171

View full text Add to dashboard Cite

ObjectiveTestosterone has a spectrum of effects on the male organism. This review attempts to determine, from published studies, the time-course of the effects induced by testosterone replacement therapy from their first manifestation until maximum effects are attained.DesignLiterature data on testosterone replacement.ResultsEffects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3–4 weeks, but maximum benefits take longer. Effects on depressive mood become detectable after 3–6 weeks with a maximum after 18–30 weeks. Effects on erythropoiesis are evident at 3 months, peaking at 9–12 months. Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy. Effects on lipids appear after 4 weeks, maximal after 6–12 months. Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months. Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years. Effects on inflammation occur within 3–12 weeks. Effects on bone are detectable already after 6 months while continuing at least for 3 years.ConclusionThe time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation. Genomic and non-genomic effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.

show abstract

Section: Time-course Of Effects On Inflammatory Factors/endothelial Mmentioning

confidence: 83%

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Saad

Aversa

Isidori

et al. 2011

European Journal of Endocrinology

198

171

View full text Add to dashboard Cite

show abstract

“…In animal (castrated male swine) models of post-angioplasty restenosis, T administration decreases neointimal formation associated with increased coronary smooth muscle apoptosis [10]. Testosterone treatment was also shown to reduce interleukin-6 and C-reactive protein levels, which may cause post-surgery restenosis [11]. Testosterone also exerts its vasodilatory effect on the vascular endothelium by the inactivation of L-type calcium channels The association between serum testosterone levels and coronary artery disease in middle-aged men and/or the activation of potassium channels.…”

Section: Discussionmentioning

confidence: 99%

Cardiac surgery The association between serum testosterone levels and coronary artery disease in middle-aged men

Durukan¹,

Gürbüz²,

Tanalp³

et al. 2013

kitp

View full text Add to dashboard Cite

StreszczenieWprowadzenie: Związek pomiędzy chorobą wieńcową a stę-żeniami androgenów w surowicy został stwierdzony przez autorów różnych badań populacyjnych. Skala Gensiniego ocenia stopień zwężeń wieńcowych, biorąc pod uwagę ich umiejscowienie. Celem niniejszej pracy było zbadanie związku pomiędzy surowiczym stężeniem testosteronu a obecnością choroby wień-cowej i jej nasileniem (według skali Gensiniego) u mężczyzn w średnim wieku. Materiał i metody: Pomiędzy październikiem 2011 r. a kwietniem 2012 r. do badania włączono 124 mężczyzn w średnim wieku (40-59 lata), u których stwierdzono bądź podejrzewano chorobę wieńcową. Wszyscy chorzy zostali poddani angiografii wieńcowej i obliczono dla nich wynik w skali Gensiniego. Zmierzono również całkowite stężenia testosteronu. Wyniki: Średni wynik pacjentów w skali Gensiniego wyniósł 44,11 ±39,08. Średnie stężenie testosteronu w plazmie wynosiło 3,51 ±1,39 ng/ml. Nie wykryto korelacji pomiędzy nasileniem choroby wieńcowej a surowiczym stężeniem testosteronu (r = -0,161, p > 0,05). Kiedy porównano pacjentów z chorobą wieńcową (wynik w skali Gensiniego ≥ 1) z pacjentami, którzy nie cierpieli na tę chorobę (n = 29, wynik skali Gensiniego: 0), okazało się, że ich średnie stężenia testosteronu w surowicy były niższe (p = 0,043). Nie wykryto korelacji pomiędzy stę-żeniami testosteronu a stężeniami cholesterolu -lipoproteiny wysokiej gęstości oraz trójglicerydów. Wystąpiła korelacja pomiędzy stężeniami testosteronu w surowicy oraz całkowitymi stężeniami cholesterolu (p = 0,008), cholesterolu -lipoproteiny niskiej gęstości (p = 0,019) oraz wskaźnikiem BMI (p = 0,001). Wnioski: Średnie stężenia testosteronu w surowicy były niż-sze u pacjentów z chorobą wieńcową. Nie udało się udokumentować ich związku z nasileniem choroby za pomocą skali Gensiniego. Słowa kluczowe: choroba wieńcowa, testosteron, skala Gensiniego. Kardiochirurgia i Torakochirurgia Polska 2013; 10 (3) 211 CARDIAC SURGERY AbstractBackground: The relation between coronary artery disease (CAD) and the levels of serum androgen has been revealed in various population studies. The Gensini coronary scoring system is used to evaluate the degree of coronary stenosis, taking into account its location and producing a numerical score. The aim of the study was to explore the association between serum testosterone levels and both the presence and severity of coronary artery disease indicated by the Gensini score in middle-aged men. Material and methods: Between October 2011 and April 2012, 124 middle-aged (40-59) male patients with known or suspected coronary artery disease were included in the study. Coronary angiography was performed in all patients, and their Gensini scores were calculated. Total serum testosterone levels were also measured. Results: The mean Gensini score of the patients was 44.11 ±39.08. The mean plasma testosterone level was 3.51 ±1.39 ng/ml. There was no correlation between the severity of coronary artery disease and the serum testosterone levels (r = -0.161, p > 0.05). When the patients with coronary ar...

show abstract

“…None reported increased inflammatory markers (Table 9). 33,142,145,[151][152][153][154][155] Summary Statement. Testosterone therapy is associated with small decreases in serum concentrations of total cholesterol, HDL cholesterol, and low-density lipoprotein cholesterol.…”

Section: Level Of Evidence Ibmentioning

confidence: 99%

Testosterone Therapy and Cardiovascular Risk: Advances and Controversies

Morgentaler

Miner

Caliber

et al. 2015

Mayo Clinic Proceedings

180

171

View full text Add to dashboard Cite

Two recent studies raised new concerns regarding cardiovascular (CV) risks with testosterone (T) therapy. This article reviews those studies as well as the extensive literature on T and CV risks. A MEDLINE search was performed for the years 1940 to August 2014 using the following key words: testosterone, androgens, human, male, cardiovascular, stroke, cerebrovascular accident, myocardial infarction, heart attack, death, and mortality. The weight and direction of evidence was evaluated and level of evidence (LOE) assigned. Only 4 articles were identified that suggested increased CV risks with T prescriptions: 2 retrospective analyses with serious methodological limitations, 1 placebo-controlled trial with few major adverse cardiac events, and 1 meta-analysis that included questionable studies and events. In contrast, several dozen studies have reported a beneficial effect of normal T levels on CV risks and mortality. Mortality and incident coronary artery disease are inversely associated with serum T concentrations (LOE IIa), as is severity of coronary artery disease (LOE IIa). Testosterone therapy is associated with reduced obesity, fat mass, and waist circumference (LOE Ib) and also improves glycemic control (LOE IIa). Mortality was reduced with T therapy in 2 retrospective studies. Several RCTs in men with coronary artery disease or heart failure reported improved function in men who received T compared with placebo. The largest meta-analysis to date revealed no increase in CV risks in men who received T and reduced CV risk among those with metabolic disease. In summary, there is no convincing evidence of increased CV risks with T therapy. On the contrary, there appears to be a strong beneficial relationship between normal T and CV health that has not yet been widely appreciated.

show abstract

The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting

Cited by 29 publications

References 28 publications

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Cardiac surgery The association between serum testosterone levels and coronary artery disease in middle-aged men

Testosterone Therapy and Cardiovascular Risk: Advances and Controversies

Contact Info

Product

Resources

About